Featured Research

Depression eased quickly with experimental drug: Works in brain like Ketamine, with fewer side effects, study suggests

Date:

December 12, 2012

Source:

NIH/National Institute of Mental Health

Summary:

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system. The findings serve as a proof of concept that targeting this system holds promise for development of a new generation of rapid antidepressants with fewer side effects than ketamine.

Share This

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

Related Articles

Existing antidepressants available through prescription, which work through the brain's serotonin system, take a few weeks to work, imperiling severely depressed patients, who can be at high risk for suicide. Ketamine also works in hours, but its usefulness is limited by its potential for dissociative side-effects, including hallucinations. It is being studied mostly for clues to how it works.

"Our findings serve as a proof of concept that we can tap into an important component of the glutamate pathway to develop a new generation of safe, rapid-acting practical treatments for depression," said Carlos Zarate, M.D., of the NIH's National Institute of Mental Health, which conducted the research.

Zarate, and colleagues, reported on their results online Dec. 1, 2012 in the journal Biological Psychiatry.

AZD6765, like ketamine, works by blocking glutamate binding to a protein on the surface of neurons, called the NMDA receptor. It is a less powerful blocker of the NMDA receptor, which may be a reason why it is better tolerated than ketamine.

About 32 percent of 22 treatment-resistant depressed patients infused with ASD6765 showed a clinically meaningful antidepressant response at 80 minutes after infusion that lasted for about half an hour -- with residual antidepressant effects lasting two days for some. By contrast, 52 percent of patients receiving ketamine show a comparable response, with effects still detectable at seven days. So a single infusion of ketamine produces more robust and sustained improvement, but most patients continue to experience some symptoms with both drugs.

However, depression rating scores were significantly better among patients who received AZD6765 than in those who received placebos. The researchers deemed this noteworthy, since, on average, these patients had failed to improve in seven past antidepressant trials, and nearly half failed to respond to electroconvulsive therapy (ECT).

The patients reported only minor side effects, such as dizziness and nausea, which were not significantly different from those experienced with the placebo.

Zarate and colleagues say their results warrant further trials with AZD6765, testing whether repeated infusions a few times per week or higher doses might produce longer-lasting results.

More From ScienceDaily

More Mind & Brain News

Featured Research

Mar. 3, 2015 — Why do people shake hands? A new study suggests one of the reasons for this ancient custom may be to check out each other's odors. Even if we are not consciously aware of this, handshaking may ... full story

Mar. 3, 2015 — Doctors write millions of prescriptions a year for drugs to calm the behavior of people with Alzheimer’s disease and other types of dementia. But non-drug approaches actually work better, and carry ... full story

Mar. 3, 2015 — Briefly counseling college students on the dangers of binge drinking is effective in lowering heavy drinking levels among many students, but only temporarily. Three out of four will be right back ... full story

Mar. 3, 2015 — Loneliness brought about by the death of a spouse can trigger a wider network of depression-like symptoms, a study has found, but authors suggest that doctors are often too quick to attribute these ... full story

Mar. 3, 2015 — Family Based Interpersonal Psychotherapy (FB-IPT) is more effective in treating preadolescent children with depression compared to child-centered therapy (CCT), a recent study has found. ... full story

Mar. 3, 2015 — Everyone worries about losing their memory as they grow older—memory loss remains one of the most common complaints of the elderly. But the molecular reasons behind the processes remain unclear, ... full story

Mar. 3, 2015 — A strong link has been made between subthreshold manic episodes and likelihood of developing bipolar disorder in children of parents with bipolar disorder. The study’s findings could improve ... full story

Mar. 2, 2015 — A newly published study is the first to report an association between bisphenol-A (BPA), a common plasticizer used in a variety of consumer food and beverage containers, with autism spectrum disorder ... full story

Mar. 2, 2015 — On Feb. 26, a picture of a cocktail dress originally uploaded to the blog Tumblr swept the Internet and managed to divide the population over a simple question: What color is the dress? Some viewers ... full story

Mar. 2, 2015 — A deficiency in the protein responsible for moving glucose across the brain's protective blood-brain barrier appears to intensify the neurodegenerative effects of Alzheimer's disease, according to a ... full story

Related Stories

Oct. 20, 2014 — A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of -- and ahead of -- its other antidepressant effects. Within 40 minutes after a single infusion of ... full story

June 17, 2014 — A compound, hydroxynorketamine (HNK), has been identified by researchers that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects ... full story

June 12, 2014 — Researchers have generated fresh insights that could aid in the development of rapid-acting antidepressants for treatment-resistant depression. The researchers found that by blocking NMDA receptors ... full story

Apr. 8, 2014 — The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect –- within 24 hours —- and was well tolerated in ... full story

Oct. 4, 2012 — Many chronically depressed and treatment-resistant patients experience immediate relief from symptoms after taking small amounts of the drug ketamine. For a decade, scientists have been trying to ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.